GEHealthcare, a leading global provider of transformational medical
technologies and services to meet the demand for increased access,
enhanced quality and more affordable healthcare around the world,
recently announced that its Discovery* PET/CT 690 and PET VCAR 2.0
were used by Professor Patrick Flamen of the Institut Jules Bordet in
Brussels in capturing the Society of Nuclear Medicine and Molecular
Imaging 2013 "Image of the Year."
Professor
Flamen's winning scan illustrated the effectiveness of radium-223
dichloride in treating bone metastases in breast cancer patients with
bone-dominant disease. It was selected as the winning image from more
than 2,000 studies.
SNMMI
said it "chooses an image that exemplifies the most cutting-edge
nuclear medicine or molecular imaging research today and that
demonstrates the ability of molecular imaging to detect, diagnose and
treat disease and help select the most appropriate therapy."
The GE
Discovery PET/CT 690 is specially designed for speed, efficiency, and
PET quantification accuracy. From short exam times through optimized
sensitivity system design and comprehensive imaging protocols, the
Discovery PET/CT 690 is the first platform focusing on quantification
accuracy without compromise by providing intelligent PET and CT
iterative reconstruction, respiratory motion management solutions,
and integrated PET calibration technologies. PET VCAR 2.0 is the
latest visualization and analytical monitoring solution featuring
both PERCIST and EORTC standards helping physicians in assessing
disease progression or response to therapy.
Another
of GE Healthcare world-class imaging technology is its GE Healthcare
Discovery PET/CT 710, which Helen Keller Hospital has recently
acquired. The unit features 64 slice imaging capabilities and is
designed to comfortably accommodate larger individuals. The PET/CT
710 combines the anatomical information from the CT and functional
information from the PET to create a combined image during one scan.
The PET/CT 710 allows clinicians to
monitor progress and fine tune treatment plans. The advantage for
physicians is the ability to more accurately differentiate between
benign and malignant tumors. Due to precise imaging capabilities,
surgeons have the ability to determine the exact location to perform
an invasive procedure. Radiation oncologists can pinpoint radiation
fields to the degree that treatment reaches all the cancer cells with
minimal damage to surrounding healthy tissue.
Doug Arnold, Helen Keller Hospital
president and CEO, said “We are thrilled to bring this
state-of-the-art diagnosis and treatment tool to the Shoals. The
capabilities of the PET/CT 710 far surpass any currently in Northwest
Alabama and will allow our patients to stay close to home.”
Such is GE Healthcare's commitment
to providing the best lifecare solutions helping medical
professionals deliver great, affordable healthcare to their patients.
Sources:
No comments:
Post a Comment